Early revascularization in acute myocardial infarction complicated by cardiogenic shock

被引:2127
作者
Hochman, JS
Sleeper, LA
Webb, JG
Sanborn, TA
White, HD
Talley, JD
Buller, CE
Jacobs, AK
Slater, JN
Col, J
McKinlay, SM
LeJemtel, TH
机构
[1] Columbia Univ, St Lukes Roosevelt Hosp Ctr, New York, NY 10025 USA
[2] Columbia Univ, New York, NY USA
[3] New England Res Inst, Watertown, MA 02172 USA
[4] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
[5] New York Hosp, Cornell Med Ctr, New York, NY USA
[6] Green Lane Hosp, Auckland 3, New Zealand
[7] Univ Arkansas, Little Rock, AR 72204 USA
[8] Univ British Columbia, Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada
[9] Boston Med Ctr, Boston, MA USA
[10] Clin Univ St Luc, B-1200 Brussels, Belgium
[11] Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词
D O I
10.1056/NEJM199908263410901
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The leading cause of death in patients hospitalized for acute myocardial infarction is cardiogenic shock. We conducted a randomized trial to evaluate early revascularization in patients with cardiogenic shock. Methods Patients with shock due to left ventricular failure complicating myocardial infarction were randomly assigned to emergency revascularization (152 patients) or initial medical stabilization (150 patients). Revascularization was accomplished by either coronary-artery bypass grafting or angioplasty. Intraaortic balloon counterpulsation was performed in 86 percent of the patients in both groups. The primary end point was mortality from all causes at 30 days. Six-month survival was a secondary end point. Results The mean (+/-SD) age of the patients was 66+/-10 years, 32 percent were women, and 55 percent had been transferred from other hospitals. The median time to the onset of shock was 5.6 hours after infarction, and most infarcts were anterior in location. Ninety-seven percent of the patients assigned to revascularization underwent early coronary angiography, and 87 percent underwent revascularization; only 2.7 percent of the patients assigned to medical therapy crossed over to early revascularization without clinical indication. Overall mortality at 30 days did not differ significantly between the revascularization and medical-therapy groups (46.7 percent and 56.0 percent, respectively; difference, -9.3 percent; 95 percent confidence interval for the difference, -20.5 to 1.9 percent; P = 0.11). Six-month mortality was lower in the revascularization group than in the medical-therapy group (50.3 percent vs. 63.1 percent, P=0.027). Conclusions In patients with cardiogenic shock, emergency revascularization did not significantly reduce overall mortality at 30 days. However, after six months there was a significant survival benefit. Early revascularization should be strongly considered for patients with acute myocardial infarction complicated by cardiogenic shock. (N Engl J Med 1999;341:625-34.) (C) 1999, Massachusetts Medical Society.
引用
收藏
页码:625 / 634
页数:10
相关论文
共 38 条
[1]   Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: In-hospital and long-term survival [J].
Antoniucci, D ;
Valenti, R ;
Santoro, GM ;
Bolognese, L ;
Trapani, M ;
Moschi, G ;
Fazzini, PF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :294-300
[2]   RESTRICTED SEQUENTIAL PROCEDURES [J].
ARMITAGE, P .
BIOMETRIKA, 1957, 44 (1-2) :9-26
[3]   Use of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock [J].
Barron, HV ;
Pirzada, SR ;
Lomnitz, DJ ;
Every, NR ;
Gore, JM ;
Chou, TM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :135A-135A
[4]   A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction [J].
Becker, RC ;
Gore, JM ;
Lambrew, C ;
Weaver, WD ;
Rubison, RM ;
French, WJ ;
Tiefenbrunn, AJ ;
Bowlby, LJ ;
Rogers, WJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (06) :1321-1326
[5]  
Berger PB, 1997, CIRCULATION, V96, P122
[6]  
Betriu A, 1997, NEW ENGL J MED, V336, P1621
[7]  
Betriu A, 1997, NEW ENGL J MED, V337, P287
[8]  
BOLOOKI H, 1989, CIRCULATION S2, V76, P37
[9]  
Breslow NE, 1980, IARC SCI PUBLICATION, V32
[10]   THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE [J].
CHESEBRO, JH ;
KNATTERUD, G ;
ROBERTS, R ;
BORER, J ;
COHEN, LS ;
DALEN, J ;
DODGE, HT ;
FRANCIS, CK ;
HILLIS, D ;
LUDBROOK, P ;
MARKIS, JE ;
MUELLER, H ;
PASSAMANI, ER ;
POWERS, ER ;
RAO, AK ;
ROBERTSON, T ;
ROSS, A ;
RYAN, TJ ;
SOBEL, BE ;
WILLERSON, J ;
WILLIAMS, DO ;
ZARET, BL ;
BRAUNWALD, E .
CIRCULATION, 1987, 76 (01) :142-154